Quantcast

Latest Uric acid Stories

2009-02-24 08:40:00

EXTON, Pa., Feb. 24 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): Uloric(R). Takeda Pharmaceutical Company Limited announced that they received FDA approval for Uloric(R) (generic name: febuxostat) on February 13, 2009. Uloric(R) is indicated for the chronic management of hyperuricemia associated with gout and represents the first product for gout that has been approved in over forty years. LaunchTrends(TM): Uloric(R) is a three...

2009-02-14 13:27:05

The U.S. Food and Drug Administration has approved a new drug for gout, the first new prescription for the painful condition in 40 years, its maker says. Takeda Pharmaceuticals North America Inc. of Deerfield, Ill., said Friday its Uloric drug has been approved by the FDA for the more than 5 million U.S. victims of gout, a malady characterized by intense pain, inflammation and warmth in affected joints, the Chicago Tribune reported. The newspaper said most doctors use well-established...

2009-02-13 19:29:00

First new treatment option in more than 40 years, marking second FDA approval for Takeda within one month DEERFIELD, Ill., and OSAKA, Japan, Feb. 13 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC(R) (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral...

2009-01-27 15:40:00

PARKERSBURG, W. Va., Jan. 27 /PRNewswire/ -- The C8 Science Panel has completed a new study on uric acid and C8 and C8S, based on existing data from the C8 Health Project. While increased uric acid is associated with higher levels of C8 and C8S, the data are not sufficient to show that these chemicals can cause an increase in uric acid. The Science Panel team recently completed a study on the relationship between uric acid and C8 (also known as PFOA) and C8S (also known as PFOS) in the blood...

2008-12-06 11:00:00

- Results Presented at ASH Annual Meeting - SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol alone (p=0.0012). The...

2008-10-27 09:00:41

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. today announced that data from its pegloticase pivotal clinical studies in treatment-failure gout (TFG) patients was presented at scientific sessions during the annual meeting of the American College of Rheumatology (ACR). Four presentations focused on results from the pegloticase double blind placebo controlled Phase 3 pivotal studies. Data from the interim results of the uncontrolled open label...

2008-10-27 09:00:41

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that preliminary data were presented from an ongoing Phase 1 trial of RDEA594, its lead product candidate in development for the treatment of hyperuricemia and gout, at the 2008 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in San Francisco, California. Preliminary data from a Phase 1 single ascending dose study of RDEA594 in healthy volunteers show that oral...

2008-10-07 15:15:00

U.S. and Dutch scientists have identified two genes and confirmed the role of a third in the creation of uric acid in gout, a painful form of arthritis. The researchers from the U.S. National Institutes of Health and the Netherlands Organization for Scientific Research found the three genetic variations were associated with up to a 40-fold increased risk in developing gout. The researchers said their findings suggest genetic testing might one day be used to identify individuals at risk for...

2008-09-22 09:00:58

EAST BRUNSWICK, N.J., Sept. 22, 2008 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT), announced today that four scientific abstracts on pegloticase and two scientific abstracts based on Treatment Failure Gout (TFG) will be presented at the American College of Rheumatology (ACR) 72nd Annual Scientific Meeting in San Francisco from October 24 - 29, 2008. For complete information on all six abstracts, please visit the ACR website at www.rheumatology.org. About the Phase 3 Study...

2008-09-16 09:00:53

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. announced today that the Company will present preclinical data on RDEA594, its lead product candidate for the treatment of gout, as well as preclinical data on RDEA119,its lead mitogen-activated ERK kinase (MEK) inhibitor for the treatment of inflammation associated with gouty arthritis, at the 2008 American College of American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related